Alma Unveils Alma IQ at Eighth Global Alma Academy in Dubrovnik
The next-generation skin analysis platform, set to redefine the aesthetic consultation experience
CAESAREA, Israel, May 27, 2025 /PRNewswire/ -- Alma, a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, has officially launched Alma IQ, its next-generation imaging platform, at the eighth Alma Academy, held in Dubrovnik, Croatia. The event gathered nearly 400 physicians and partners from over 46 countries, marking one of Alma's largest global educational event to date.
Introduced to a global audience through exclusive live demonstrations, Alma IQ, redefines how practitioners and patients approach aesthetic care from the very first consultation. By delivering real-time, high-definition insights beneath the skin's surface, the platform reveals what the eye cannot see, empowering aesthetic professionals to make informed decisions with unprecedented precision.
At the core of Alma IQ is a powerful multi-modal imaging system developed in collaboration with Sylton, a global leader in aesthetic skin visualization. In under 10 seconds, it captures high-resolution images using specialized light modes: True UV, Cross Polarized, Parallel Polarized, and proprietary 360° Light Technology. These reveal skin aspects from texture and pigmentation to inflammation and vascularity, providing a comprehensive profile that helps clinics communicate treatments clearly and foster more informed, engaged patient experiences.
"Advanced personalization starts with clarity," said Lior Dayan, CEO of Alma and Sisram Medical. "In aesthetics, the ability to truly see what lies beneath the surface is everything—it's the power to see what others can't, and to treat what others don't."
He continued: "Alma IQ delivers that clarity in a way that's both immediate and deeply personal. This is more than technology. It's a shift in how we connect and communicate with patients. It transforms the consultation into a moment of insight and trust—establishing a new foundation for intelligent, personalized aesthetic care."
Recognized as the industry's leading global education forum, this year's summit, held from May 22-25, featured 19 internationally renowned experts, including Prof. Ofir Artzi (Israel), Dr. Pina Panchal (U.S.), Dr. Fatima Aguero (Paraguay), and Dr. Chytra Anand (India). In alignment with this year's theme, "The Art of the Patient," each shared advanced clinical strategies and uncovered patient perspectives that put personalization at the forefront of the practice. Among the topics covered were skin aging, pigmentation, scarring, skin tightening, and rejuvenation.
The event also featured live demonstrations of Alma's award-winning portfolio of technologies including Alma Harmony, the multi-application platform renowned for its versatility in aesthetic and skin rejuvenation treatments, alongside Harmony Bio-Boost, the brand's signature facial designed to deliver plump, glowing skin with no downtime.
Attendees also experienced the global debut of Alma IQ, Alma Hybrid, renowned for its precision in treating scars as well as Alma PrimeX and Opus, both offering advanced, non-invasive solutions for skin tightening, resurfacing, and full-body rejuvenation.
About Alma Academy
Recognized as the leading professional academy event in the aesthetic industry, Alma Academy is designed to shape the next era of aesthetic medicine through clinical mastery, innovation, and global collaboration. Held annually in key international hubs, including Greece, Spain, Dubai, North America, Italy, and Thailand, the Academy brings together the world's foremost practitioners for a dynamic platform of hands-on training, real-world protocols, and expert-led dialogue.
About Alma
Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of-the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
3 hours ago
- Korea Herald
International Healthcare Week 2025 - Innovate, Collaborate, And Elevate Healthcare In ASEAN And Beyond
KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ -- International Healthcare Week (IHW) 2025, Southeast Asia's premier healthcare event, will be held from July 16 to 18 at the Malaysia International Trade and Exhibition Centre (MITEC), Kuala Lumpur. Organised by Informa Markets, IHW 2025 is set to be a transformative platform that accelerates healthcare innovation, fosters regional collaboration, and drives economic growth throughout the healthcare sector. With over 900 leading local, regional, and international exhibitors showcasing more than 15,000 products and services, and an expected attendance of 21,000 professionals from over 50 countries, IHW 2025 offers unmatched opportunities for networking, knowledge exchange, and business development. One Venue, Five Healthcare Trade Sh ows, One Unmissable Event IHW 2025 integrates five flagship international trade exhibitions under one roof, covering the entire healthcare value chain and enhancing opportunities to learn, collaborate, invest, and showcase innovations across healthcare sectors, noted Rungphech (Rose) Chitanuwat, Regional Portfolio Director – ASEAN at Informa Markets. Each exhibition is complemented by dedicated conferences tailored to the specific needs and developments of their respective industries: "Participants at IHW 2025 will have the unique advantage of exploring multiple healthcare sectors and attending 125 conference sessions tailored to diverse healthcare domains - all within a single venue. This integrated format eliminates the need to travel between separate events, allowing attendees to maximise their time and resources while gaining a comprehensive understanding of the latest market trends, innovative technologies, and cutting-edge solutions," said Rungphech. Malaysia – Leading the Way in Healthcare "Malaysia's robust healthcare market expansion, flourishing medical tourism sector, strategic regional location, supportive government initiatives, and ongoing advancements in healthcare infrastructure collectively establish the country as an ideal host for IHW 2025. This event will further cement Malaysia's status as a premier healthcare hub in ASEAN and serve as a gateway for global healthcare collaboration," highlighted Rungphech. As ASEAN Chair in 2025, Malaysia plays a pivotal role in promoting regional healthcare cooperation, addressing critical challenges such as supply chain resilience, digital health adoption, and sustainable health financing through platforms like the EU-ASEAN Health Summit. Strengthening Regional Healthcare Cooperation IHW 2025 is fully aligned with ASEAN's strategic objectives to bolster healthcare systems, enhance health outcomes, and promote equitable access across member states. The event serves as a vital platform for fostering networking and partnerships essential for advancing cross-border collaboration, policy harmonization, and increased investment in healthcare infrastructure and services. This collaborative environment supports key regional initiatives including digital health integration, combating non-communicable diseases, and pandemic preparedness-priorities underscored by recent public health challenges in Southeast Asia. MATRADE: A Strong and Strategic Partner As a valued partner of International Healthcare Week 2025, the Malaysia External Trade Development Corporation (MATRADE), Malaysia's national trade promotion agency, plays a crucial role in enhancing Malaysia's global visibility and reputation in the healthcare sector. Through promotion and fostering international collaborations, MATRADE actively positions Malaysia as a regional medical hub for Southeast Asia and beyond. YB Dato' Seri Reezal Merican Naina Merican, Chairman of MATRADE, emphasized the significance of IHW 2025, stating, "International Healthcare Week serves as a powerful platform that elevates Malaysia's standing as a regional leader in healthcare and medical services. This leading event not only promotes innovation but also directly contributes to our nation's economic growth by attracting world-class exhibitors, regional and international delegates, and top healthcare experts to Malaysia—fueling trade, knowledge sharing, and industry advancement." Join Us at IHW 2025 Healthcare professionals are invited to register online at to secure their place at this free-to-attend event. Don't miss this exceptional opportunity to contribute to shaping the future of the vibrant and evolving healthcare industry in ASEAN and beyond! About Informa Markets Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. We provide marketplace participants around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, targeted digital services and actionable data solutions. We connect buyers and sellers across more than a dozen global verticals, including Pharmaceuticals, Boating, Food, Fashion, and Infrastructure. As the world's leading market-making company, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
Korea Herald
3 hours ago
- Korea Herald
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3 rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. "The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance," said Dr. Anna Jo, CEO. "The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization"
Korea Herald
a day ago
- Korea Herald
Tianfu Rapoil Shines at Hong Kong Hometown Market Carnival
HONG KONG, June 1, 2025 /PRNewswire/ -- This is a report from Xinhuanet: Co-organized by 30 provincial-level hometown associations in Hong Kong, the "Third Hometown Market Carnival" was kicked off on June 1 in Victoria Park, marking the beginning of the five-day event. The Sichuan Provincial Grain and Material Reserve Bureau showcased its premium products under the 'Tianfu Rapoil' brand at the event, becoming the star attraction in this year. At the event, Tianfu Rapoil brought nearly 2,000 products, ranging from 'Traditional Small-Pressed Rich-Aromatic Rapeseed Oil' made using non-heritage pressing techniques, to low-erucic acid rapeseed oil, and small-packaged rapeseed oil specifically designed for younger consumers. On-site, residents and tourists participated in 'Come to Play and Win Oil in Victoria Park'. They not only won Tianfu Rapoil products but also received its limited-edition cultural and creative merchandise. Items such as umbrellas, folding fans, and canvas bags featuring panda patterns became the most sought-after items at the event. This year's Hong Kong Hometown Market Carnival features a special Chinese Food Street, with 30 food stalls offering cuisines from all over China. When Tianfu Rapoil meets regional specialities such as Xinjiang lamb skewers, Shaanxi Roujiamo, and Hunan Changde rice noodles, magical sparks occur. At Xinjiang association stall, chefs blended Tianfu rapeseed oil with cumin and chili powder to create a secret sauce brushed onto sizzling lamb skewers, drawing a snaking line of eager customers. At Shaanxi association stall, chefs tried Tianfu rapeseed oil to bake Roujiamo, praised by diners as a 'soulful carb bomb'. At Hunan association stall, chefs used Tianfu rapeseed oil to prepare the special topping for Changde rice noodles, delighting noodle lovers with its fragrant and refreshing taste. During the event, procurement managers from local Hong Kong catering groups and buyers from high-end supermarkets were drawn by the aroma. "The fragrance of Tianfu Rapoil is unique. After testing it in cooking, we noticed a significant improvement in the dishes' flavor," said a procurement representative from a well-known chain restaurant, who expressed immediate interest in establishing a stable supply channel after learning about the oil's production process and quality standards. The flood of partnership inquiries reflects the robust strength of Sichuan's rapeseed industry. As the province with the largest rapeseed cultivation area and the highest rapeseed oil consumption in China, Sichuan has in recent years taken the Tianfu Rapoil initiative as a starting point to drive the upgrading of the entire industrial chain, and enabled Tianfu Rapoil to stand out in the domestic edible oil sector, winning the 'China Grain and Oil Influential Public Brand' award for five consecutive years, with a brand value exceeding 10 billion yuan.
